何攀,陈海威,杨俊杰,高磊,郭军,陈韵岱,汪奇

• 1:中国人民解放军总医院第一医学中心心血管内科
• 2:中国人民解放军医学院

摘要(Abstract)：

目的 探讨准分子激光冠状动脉成形术联合药物涂层球囊的治疗策略在复发性支架内再狭窄病变中运用的安全性和疗效。方法 回顾性连续纳入2019年10月至2023年4月在中国人民解放军总医院第一医学中心采用准分子激光冠状动脉成形术联合药物涂层球囊进行治疗的27例复发性支架内再狭窄患者（30处病变）的临床资料进行分析。收集患者基线资料、冠状动脉造影及介入数据、住院期间并发症发生数据，并在术后1、3、6个月进行随访，记录重大临床事件发生情况。结果 27例患者，平均年龄（66.4±9.8）岁，共计30处（100%）病变均取得了手术成功和治疗成功，患者住院期间无急性心肌梗死、无冠状动脉穿孔及心脏压塞、无紧急的靶病变再次血运重建、无死亡。6个月的随访，无急性心肌梗死、无死亡发生，共2例患者（共2处病变）接受了靶病变再次血运重建（1例患者进行了重复的药物球囊扩张术，1例接受了冠状动脉旁路移植术）。结论 准分子激光冠状动脉成形术联合药物涂层球囊是治疗复发性支架内再狭窄安全、有效的治疗策略，但尚需更多的研究进一步验证。

关键词(KeyWords)： 复发性支架内再狭窄;准分子激光冠状动脉成形术;药物涂层球囊

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 何攀,陈海威,杨俊杰,高磊,郭军,陈韵岱,汪奇

参考文献(References)：

• [1]Moussa ID,Mohananey D,Saucedo J,et al.Trends and outcomes of restenosis after coronary stent implantation in the United States[J].J Am Coll Cardiol,2020,76(13):1521-1531.DOI:10.1016/j.jacc.2020.08.002.
• [2]Neumann FJ,Sousa-Uva M,Ahlsson A,et al.2018 ESC/EACTS guidelines on myocardial revascularization[J].Eur Heart J,2019,40(2):87-165.DOI:10.1093/eurheartj/eby394.
• [3]Giacoppo D,Alfonso F,Xu B,et al.Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis[J].J Am Coll Cardiol,2020,75(21):2664-2678.DOI:10.1016/j.jacc.2020.04.006.
• [4]Ali RM,Abdul Kader M,Wan Ahmad WA,et al.Treatment of coronary drug-eluting stent restenosis by a sirolimus-or paclitaxel-coated balloon[J].JACC Cardiovasc Interv,2019,12(6):558-566.DOI:10.1016/j.jcin.2018.11.040.
• [5]Kawamoto H,Ruparelia N,Latib A,et al.Drug-coated balloons versus second-generation drug-eluting stents for the management of recurrent multimetal-layered in-rtent restenosis[J].JACC Cardiovasc Intern,2015,8(12):1586-1594.DOI:10.1016/j.j cin.2015.04.032.
• [6]Bossi I,D'Anna M.Vaccaro V,et al,Paclitaxel-coated balloons for in-stent resteno sis treatment:long-term clinical results and predictors of recurrent target lesion revascularization[J].G Ital Cardiol(Rome),2018,19(4):232-238.DOI:10.1714/2898.29217.
• [7]Golino L,Caiazzo G,Calabro P,et al.Excimer laser technology in percutaneous coronary interventions:cardiovascular laser society's position paper[J].Int J Cardiol,2022,350:19-26.DOI:10.1016/j.ijcard.2021.12.054.
• [8]Singh AD,Singal AK,Mian A,et al.Recurrent drugeluting stent in-stent restenosis:a state-of-the-art review of pathophysiology,diagnosis,and management[J].Cardiovasc Revasc Med,2020,21(9):1157-1163.DOI:10.1016/j.carrev.2020.01.005.
• [9]Zhang H,Zhang Y,Tian T,et al.Comparison of recurrent with first-time in-stent restenosis[J].Am J Cardiol,2023,206:168-174.DOI:10.1016/j.amjcard.2023.08.131.
• [10]Kubo S,Kadota K,Otsuru S,et al.Optimal treatment of recurrent restenosis lesions after drug-eluting stent implantation for in-stent restenosis lesions[J].Euro Intervention,2013,9(7):788-796.DOI:10.4244/EIJV9I7A131.
• [11]陈韵岱,邱春光,唐强,等.药物涂层球囊临床应用中国专家共识(第二版)[J],中国介入心脏病学杂志,2023,31(6):413-426.DOI:10.3969/j.issn.1004-8812.2023.06.003.
• [12]Negi SI,Torguson R,Gai J,et al.Intracoronary brachytherapy for recurrent drug-eluting stent failure[J].JACC Cardiovasc Interv,2016,9(12):1259-1265.DOI:10.1016/j.jcin.2016.03.018.
• [13]Shlofmitz E,Iantorno M,Waksman R.Restenosis of drugeluting stents:a new classification system based on disease mechanism to guide treatment and state-of-the-art review[J].Circ Cardiovasc Interv,2019,12(8):e007023.DOI:10.1161/CIRCINTERVENTIONS.118.00702 3.
• [14]Kang SJ,Mintz GS,Park DW,et al.Mechanisms of in-stent restenosis after drug-eluting stent implantation:intravascular ultrasound analysis[J].Circ Cardiovasc Interv,2011,4(1):9-14.DOI:10.1161/CIRCINTERVENTIONS.110.940 320.
• [15]Yin D,Mintz GS,Song L,et al.In-stent restenosis characteristics and repeat stenting underexpansion:insights fromoptical coherence tomography[J].EuroIntervention,2020,16(4):e335-e343.DOI:10.4244/EIJ-D-18-01191.
• [16]杨旺伟,刘毅,李妍,等.支架内再狭窄38例光学相干断层成像影像分析[J].中国介入心脏病学杂志,2020,28(3):138-143.DOI:10.3969/j.issn.1004-8812.2020.03.004.
• [17]何攀,汪奇.准分子激光辅助治疗冠状动脉支架内再狭窄的研究进展[J].中国介入心脏病学杂志,2022,30(9):693-696.DOI:10.3969/j.issn.1004-8812.2022.09.011.
• [18]Nishino M,Lee Y,Nakamura D,et al.Differences in optical coherence tomographic findings and clinical outcomes between excimer laser and cutting balloon angioplasty for focal in-stent restenosis lesions[J].J Invasive Cardiol,2012,24(10):478-483.
• [19]Ishihara T,Dohi T,Nakamura D,et al.Impact of in-stent tissue characteristics on excimer laser coronary angioplasty prior to drug-coated balloon treatment[J].Int J Cardiol,2021,339:28-32.DOI:10.1016/j.ijcard.2021.07.019.
• [20]Sato T,Tsuchida K,Yuasa S,et al.The effect of the debulking by excimer laser coronary angioplasty on long-term outcome compared with drug-coating balloon:insights from optical frequency domain imaging analysis[J].Lasers Med Sci,2020,35(2):403-412.DOI:10.1007/s10103-019-02833-1.
• [21]Viceconte N,Biscione C,Tarsia G,et al.Laser"explosion"technique for treatment of unexpanded coronary stent[J].Int J Cardiol,2011,149(3):395-397.DOI:10.1016/j.ijcard.2011.03.021.
• [22]Latib A,Takagi K,Chizzola G,et al.Excimer Laser LEsion modification to expand non-dilatable stents:the ELLEMENT registry[J].Cardiovasc Revasc Med,2014,15(1):8-12.DOI:10.1016/j.carrev.2013.10.005.
• [23]Lee T,Shlofmitz RA,Song L,et al.The effectiveness of excimer laser angioplasty to treat coronary in-stent resteno sis with peri-stent calcium as assessed by optical coherence tomography[J].EuroIntervention,2019,15(3):e279-e288.DOI:I0.4244/EIJ-D-18-00139.
• [24]Albertal M,Abizaid A,Munoz JS,et al.A novel mechanism explaining early lumen loss following balloon angioplasty for the treatment of in-stent restenosis[J].Am J Cardiol,2005,95(6):751-754.DOI:10.1016/j.amjcard.2004.11.028.